BioPharma Dive 27 feb 2026 Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
BioPharma Dive 6 feb 2026 White House’s online service for drug sales debuts with limited impact on prices
BioPharma Dive 14 ene 2026 JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view